Day: April 8, 2022

ATLANTA, April 08, 2022 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, today announced that it will participate in Noble Capital’s 18th Annual Microcap Investor Conference April 20-21, 2022 in Miami, Florida. As part of this event, management will host a webcast presentation at 10:00 a.m. Eastern Time on the 20th. Institutional investors are welcome to participate in one-on-one meetings and, if they do not have a Noble contact, may call or email DLH investor relations for assistance. About DLHDLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 April 2022 Fagron publishes agenda 2022 annual general meeting and extraordinary general meeting The Board of Directors of Fagron NV (Fagron) invites the holders of shares and subscription rights of Fagron to attend the annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 9 May 2022. Both meetings will be held in hybrid format. AgendaThe agenda includes the discussion of the annual report (published today in Dutch), the approval of the annual financial statements and the dividend proposal of €0.20 for the fiscal year 2021, and the proposal for several appointments. As announced earlier, the Board of Directors will propose to appoint Vera Bakker, Ann Desender, and Neeraj Sharma as independent and non-executive directors...

FLORHAM PARK, N.J., April 08, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that on April 6, 2022 PDS Biotech granted nonstatutory stock options to (a) Robert Imani, M.D., PhD, PDS Biotech’s Vice President Medical Director to purchase 70,000 shares of PDS Biotech common stock, and (b) Paul Ivany, PDS Biotech’s Senior Director Manufacturing Operations, to purchase 50,000 shares of PDS Biotech’s common stock, in each case, as a material inducement to their employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s...

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:00 am Eastern Time.Conference Call & Webcast Details:     Date: Thursday, April 14Time: 8:00 am Eastern TimeToll Free: 877-451-6152International: 201-389-0879Conference ID: 13728822Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1542381&tp_key=4941bdf92aAbout BeyondSpringHeadquartered in New York City, BeyondSpring...

GLEN MILLS, Pa., April 08, 2022 (GLOBE NEWSWIRE) — Axalta (NYSE: AXTA), a leading global supplier of liquid and powder coatings, will release its first-quarter 2022 financial results after the close of trading on Monday, April 25. The release and supporting materials will be posted to the Investor Relations portion of axalta.com. In addition, the company will host a conference call at 8 a.m. ET on Tuesday, April 26, 2022. Robert W. Bryant, Chief Executive Officer, and Sean Lannon, Chief Financial Officer, will review the company’s financial performance for the period. A live webcast of the conference call will also be available online at www.axalta.com/investorcall. The dial-in phone number for the conference call is 201-689-8560. For those unable to participate, a replay of the call will be available through May 3, 2022....

ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to ~9 months from historical data with KEYTRUDA® alone Median overall survival of 33.7 months in all mCRPC patients treated with ADXS-PSA in combination with KEYTRUDA®, as previously reported MONMOUTH JUNCTION, N.J., April 08, 2022 (GLOBE NEWSWIRE) — Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced the publication of results of their KEYNOTE-46 Phase 1/2 open-label, double-arm...

Event will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am ET AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time. The webinar will feature a presentation from medical expert David Spigel, MD, of the Sarah Cannon Research Institute, who will discuss Molecular Templates’ program, MT-6402 (targeting PD-L1), and the implications of the Phase...